Inhibrx Inc Ordinary Shares INBX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INBX is a good fit for your portfolio.
News
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates WRK, TGAN, ANSS, INBX
-
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates TAST, MDC, INBX
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates MDC, INBX, KAMN, HAYN
-
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - INBX, KAMN, JNPR, HAYN
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates INBX, BATL, KAMN
-
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZB
Trading Information
- Previous Close Price
- $34.01
- Day Range
- $33.87–34.45
- 52-Week Range
- $14.31–39.79
- Bid/Ask
- $33.60 / $34.15
- Market Cap
- $1.62 Bil
- Volume/Avg
- 246,595 / 459,682
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 894.17
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 172
- Website
- https://www.inhibrx.com
Comparables
Valuation
|
Metric
|
INBX
|
VOR
|
PRLD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 37.19 | 0.81 | 0.89 |
Price/Sales | 894.17 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
INBX
VOR
PRLD
Financial Strength
|
Metric
|
INBX
|
VOR
|
PRLD
|
|---|---|---|---|
Quick Ratio | 4.95 | 8.81 | 10.67 |
Current Ratio | 5.25 | 9.04 | 10.79 |
Interest Coverage | −6.90 | — | — |
Quick Ratio
INBX
VOR
PRLD
Profitability
|
Metric
|
INBX
|
VOR
|
PRLD
|
|---|---|---|---|
Return on Assets (Normalized) | −77.08% | −41.83% | −38.93% |
Return on Equity (Normalized) | −500.57% | −51.69% | −43.41% |
Return on Invested Capital (Normalized) | −81.45% | −47.03% | −42.59% |
Return on Assets
INBX
VOR
PRLD
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dxpbyjvf | Btrn | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pckwxrq | Kbthvrm | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zgtfxwc | Tmsxw | $103.7 Bil | |
MRNA
| Moderna Inc | Nnsxlnqn | Sbn | $47.9 Bil | |
ARGX
| argenx SE ADR | Ghwwgwj | Xqkzx | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Cvmwsxlq | Hlxy | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zzthjwnx | Pbfjskz | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gfhbhygyt | Fthts | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yznfzpzrp | Slgsb | $12.8 Bil | |
INCY
| Incyte Corp | Kkmvqykhr | Cfhzxq | $12.1 Bil |